The rationale for ROR1 as CAR-T target:
1) Expression restricted to fetus and tumors. If ADC's are safe CARs should be too.
2) ADCs nabbed monotherapy CRs in MCL.
3) Diverse tumors evolve to express ROR1 as they advance.
4) W/in heterogeneous ROR1 found on tumor stem-cells. $ONCT
Re #4, if it's true that tumor stem cells often rely on ROR1 to maintain their pathological stemness, and stemness confers flexibility for relapse, then responses to ROR1 inhibition should be durable.

See durability below. Ibrutinib monotherapy median DoR is 17.5 months.
$ONCT data is still maturing. Note that three PRs converted to CR at 7, 9, and 12 months. Only one PR progressed. And multiple PRs are yet young. Today: 7/15 CR. Ultimately? Could be 10/15.

ROR1 inhibition induces differentiation more than cytotoxicity. It's gentle/gradual MoA.
$ONCT data is still maturing. Note that three PRs converted to CR at 7, 9, and 12 months. Only one PR progressed. And multiple PRs are yet young. Today: 7/15 CR. Ultimately? Could be 10/15. ROR1 inhibition induces differentiation more than cytotoxicity. It's gentle/gradual MoA.
$ONCT data is still maturing. Note that three PRs converted to CR at 7, 9, and 12 months. Only one PR progressed. And multiple PRs are yet young. Today: 7/15 CR. Ultimately? Could be 10/15. ROR1 inhibition induces differentiation more than cytotoxicity. It's gentle/gradual MoA.
Advantage of diff modalities for targeting ROR1:

Naked antibody: attractive safety in combos w/ hints of reducing ibrutinib toxicity (maybe by inducing differentiation of cells that would've otherwise been killed by ibrutinib).
ADC: More potent than naked antibody, probably safe enough to combine w/ same treatments as naked antibody, maybe effective enough in combo that preclude necessity for CAR-T, especially if tumors are too heterogenous for CAR-T monotherapy to work.
CAR-T: ROR1 is not expressed on healthy tissue so why not hit it with the bazooka? And if tumor stem cells - which resist existing SoC - do indeed rely on ROR1, then a potent ROR-1 CAR-T + cytotoxic SoC combo could overcome the problem of solid tumor heterogeneity for real CRs.
CAR-T: ROR1 is not expressed on healthy tissue so why not hit it with the bazooka? And if tumor stem cells - which resist existing SoC - do indeed rely on ROR1, then a potent ROR-1 CAR-T + cytotoxic SoC combo could overcome the problem of solid tumor heterogeneity for real CRs.
CAR-T: ROR1 is not expressed on healthy tissue so why not hit it with the bazooka? And if tumor stem cells - which resist existing SoC - do indeed rely on ROR1, then a potent ROR-1 CAR-T + cytotoxic SoC combo could overcome the problem of solid tumor heterogeneity for real CRs.
CAR-T: ROR1 is not expressed on healthy tissue so why not hit it with the bazooka? And if tumor stem cells - which resist existing SoC - do indeed rely on ROR1, then a potent ROR-1 CAR-T + cytotoxic SoC combo could overcome the problem of solid tumor heterogeneity for real CRs.
$ONCT's ROR1 CAR-T hits the clinic mid-2021. The only other ROR1 CAR-T is Juno's, which initiated in 2016. When data? Dunno. But note the breadth of signal finding: lung, breast, heme, and "malignant solid neoplasm".

Q: did Merck/Boehringer know what Juno's seen?
$ONCT's ROR1 CAR-T hits the clinic mid-2021. The only other ROR1 CAR-T is Juno's, which initiated in 2016. When data? Dunno. But note the breadth of signal finding: lung, breast, heme, and "malignant solid neoplasm". Q: did Merck/Boehringer know what Juno's seen?
$ONCT's ROR1 CAR-T hits the clinic mid-2021. The only other ROR1 CAR-T is Juno's, which initiated in 2016. When data? Dunno. But note the breadth of signal finding: lung, breast, heme, and "malignant solid neoplasm". Q: did Merck/Boehringer know what Juno's seen?
$ONCT's ROR1 CAR-T hits the clinic mid-2021. The only other ROR1 CAR-T is Juno's, which initiated in 2016. When data? Dunno. But note the breadth of signal finding: lung, breast, heme, and "malignant solid neoplasm". Q: did Merck/Boehringer know what Juno's seen?
You can follow @brendan_49.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.